Related Experiment Video
Updated: Apr 25, 2026

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
Published on: May 20, 2014
Oxysterols synergize with statins by inhibiting SREBP-2 in ovarian cancer cells
Cinzia Casella1, Daniel H Miller1, Kerry Lynch1
1Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI 02903, USA.
Objective:
Determine mechanisms responsible for enhanced statin efficacy in a novel statin combination we name STOX (STatin-OXysterol).
Methods:
Ovarian cancer cell lines were treated with combinations of statins and oxysterols. Cell viability was determined by a modified MTT assay. Apoptosis was evaluated by immunoblotting of PARP and DAPI-mediated visualization of apoptotic nuclei. STOX effects on the expression of genes of the mevalonate pathway were assessed by real-time qPCR and immunoblotting. siRNA-mediated gene silencing was used to test the involvement of oxysterol-mediated repression of SREBP-2 in STOX synergy. The impact of statin-mediated inhibition of protein prenylation and on cholesterol homeostasis was evaluated.
Results:
Oxysterols dramatically enhance cytotoxicity of statins in ovarian cancer cells through increased apoptosis. Decreased expression of SREBP-2 down-regulates the mevalonate pathway and prevents the active statin-induced sterol feedback, enhancing statin toxicity. Comparison of two ovarian cancer cell lines reveals two distinct mechanisms of statin induced toxicity, namely, dependence on protein geranylgeranylation and/or perturbation of cellular cholesterol levels.
Conclusions:
We provide evidence of statins' mechanisms of cytotoxicity in different ovarian cancer cells and discovered a new approach to significantly enhance the anti-tumor activity of statins. These observations provide a potential new path to improve statins as a treatment against ovarian cancer with obtainable dosages.
Insights
Oxysterols enhance statin effectiveness against ovarian cancer by increasing cell death. This novel STOX combination targets the mevalonate pathway, offering a promising new strategy for ovarian cancer treatment.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Statins are cholesterol-lowering drugs with potential anti-cancer properties.
- Ovarian cancer remains a significant health challenge with limited treatment options.
- Understanding drug mechanisms is crucial for developing more effective therapies.
Purpose of the Study:
- To elucidate the mechanisms behind the enhanced efficacy of a novel statin-oxysterol combination (STOX) in ovarian cancer.
- To investigate how oxysterols potentiate statin-induced cytotoxicity.
Main Methods:
- Ovarian cancer cell lines were treated with statins and oxysterols.
- Cell viability, apoptosis, and gene expression (mevalonate pathway, SREBP-2) were assessed.
- siRNA-mediated gene silencing and protein prenylation assays were employed.
Main Results:
- Oxysterols significantly increased statin-induced apoptosis and cytotoxicity in ovarian cancer cells.
- STOX treatment led to decreased SREBP-2 expression, down-regulating the mevalonate pathway and enhancing statin toxicity.
- Distinct mechanisms of statin toxicity were observed, involving protein geranylgeranylation and cholesterol homeostasis.
Conclusions:
- The study reveals mechanisms of statin cytotoxicity in ovarian cancer cells.
- The STOX combination represents a novel approach to enhance anti-tumor activity of statins.
- This strategy may offer a new therapeutic avenue for ovarian cancer treatment.
More Related Videos
07:59Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Related Concept Videos
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Oogenesis
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Ovaries
On the ovarian surface, a layer of...